In vitro activity of ceftaroline against Staphylococcus aureus isolates collected in 2012 from Latin American countries as part of the AWARE surveillance program

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 12, 2015, Pages 7873-7877

  Biedenbach, Douglas J ^a   Hoban, Daryl J ^a   Reiszner, Edina ^b   Lahiri, Sushmita D ^b,c   Alm, Richard A ^b,c   Sahm, Daniel F ^a   Bouchillon, Samuel K ^a   Ambler, Jane E ^b,d  

^a International Health Management Associates   (United States)

^b ASTRAZENECA   (United Kingdom)

^c Macrolide Pharmaceuticals   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTAROLINE FOSAMIL; DAPTOMYCIN; PENICILLIN BINDING PROTEIN 2A; TIGECYCLINE; ANTIINFECTIVE AGENT; CEFTAROLINE; CEPHALOSPORIN DERIVATIVE;

ALLOSTERISM; AMERICAN; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARGENTINA; ARTICLE; BACTERIUM ISOLATE; BRAZIL; CELL LINEAGE; CHILE; COLOMBIA; COMPARATIVE STUDY; DRUG ACTIVITY; DRUG SURVEILLANCE PROGRAM; EPIDEMIC; HOSPITAL PATIENT; HUMAN; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MULTILOCUS SEQUENCE TYPING; NONHUMAN; PRIORITY JOURNAL; SKIN STRUCTURE; VENEZUELA; CLINICAL TRIAL; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; HEALTH SURVEY; HOSPITALIZATION; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTICENTER STUDY; PENICILLIN RESISTANCE; PHYSIOLOGY; SOUTH AND CENTRAL AMERICA; STAPHYLOCOCCAL INFECTIONS;

ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; HOSPITALIZATION; HUMANS; LATIN AMERICA; METHICILLIN RESISTANCE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; PUBLIC HEALTH SURVEILLANCE; STAPHYLOCOCCAL INFECTIONS;

EID: 84954555699     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01833-15     Document Type: Article

References (38)

1. Rodvold KA, McConeghy KW. 2014. Methicillin-resistant Staphylococcus aureus therapy: past, present, and future. Clin Infect Dis 58(Suppl 1):S20-S27. http://dx.doi.org/10.1093/cid/cit614.
2. Moet GJ, Jones RN, Biedenbach DJ, Stilwell MG, Fritsche TR. 2007. Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998-2004). Diagn Microbiol Infect Dis 57:7-13. http://dx.doi.org/10.1016/j.diagmicrobio.2006.05.009.
3. Rubinstein E, Kollef MH, Nathwani D. 2008. Pneumonia caused by methicillin-resistant Staphylococcus aureus Clin Infect Dis 46(Suppl 5): S378-S385. http://dx.doi.org/10.1086/533594.
4. Klevens RM, Morrison MA, Nadle J, Petit S, Gershman K, Ray S, Harrison LH, Lynfield R, Dumyati G, Townes JM, Craif AS, Zell ER, Fosheim GE, McDougal LK, Carey RB, Fridkin SK, Active Bacterial Core Surveillance (ABCs) MRSA Investigators. 2007. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 298:1763-1771. http://dx.doi.org/10.1001/jama.298.15.1763.
5. Ray GT, Suaya JA, Baxter R. 2012. Trends and characteristic of cultureconfirmed Staphylococcus aureus infections in a large U.S. integrated health care organization. J Clin Microbiol 50:1950-1957. http://dx.doi.org/10.1128/JCM.00134-12.
6. Woods C, Colice G. 2014. Methicillin-resistant Staphylococcus aureus pneumonia in adults. Expert Rev Respir Med 8:641-651. http://dx.doi.org/10.1586/17476348.2014.940323.
7. Diekema DJ, Richter SS, Heilmann KP, Dohrn CL, Riahi F, Tendolkar S, McDanel JS, Doern GV. 2014. Continued emergence of USA300 methicillin-resistant Staphylococcus aureus in the United States: results from a nationwide surveillance study. Infect Control Hosp Epidemiol 35: 285-292. http://dx.doi.org/10.1086/675283.
8. Levesque S, Bourgault AM, Galarneau LA, Moisan D, Doualla-Bell F, Tremblay C. 2015. Molecular epidemiology and antimicrobial susceptibility profiles of methicillin-resistant Staphylococcus aureus blood culture isolates: results of the Quebec Provincial Surveillance Programme. Epidemiol Infect 143:1511-1518. http://dx.doi.org/10.1017/S095026881400209X.
9. Tadros M, Williams V, Coleman BL, McGeer AJ, Haider S, Lee C, Iacovides H, Rubinstein E, John M, Johnston L, McNeil S, Katz K, Laffin N, Suh KN, Powis J, Smith S, Taylor G, Watt C, Simor AE. 2013. Epidemiology and outcome of pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA) in Canadian hospitals. PLoS One 8:e75171. http://dx.doi.org/10.1371/journal.pone.0075171.
10. David MZ, Daum RS, Bayer AS, Chambers HF, Fowler VG, Jr, Miller LG, Ostrowsky B, Baesa A, Boyle-Vavra S, Eells SJ, Garcia-Houchins S, Gialanella P, Macias-Gil R, Rude TH, Ruffin F, Sieth JJ, Volinski J, Spellberg B. 2014. Staphylococcus aureus bacteremia at 5 US academic medical centers, 2008-2011: significant geographic variation in community-onset infections. Clin Infect Dis 15:798-807. http://dx.doi.org/10.1093/cid/ciu410.
11. Tokajian S. 2014. New epidemiology of Staphylococcus aureus infections in the Middle East. Clin Microbiol Infect 20:624-628. http://dx.doi.org/10.1111/1469-0691.12691.
12. Kollipara R, Downing C, Lee M, Guidry J, Curis S, Tyring S. 2014. Current and emerging drugs for acute bacterial skin and skin structure infections: an update. Expert Opin Emerg Drugs 19:431-440. http://dx.doi.org/10.1517/14728214.2014.955015.
13. Rincon S, Panesso D, Diaz L, Carvajal LP, Reyes J, Munita JM, Arias CA. 2014. Resistance to "last resort" antibiotics in Gram-positive cocci: the post-vancomycin era. Biomedica 34(Suppl 1):191-208. http://dx.doi.org/10.7705/biomedica.v34i0.2210.
14. Arshad S, Hartman P, Zervos MJ. 2014. A novel treatment option for MRSA pneumonia: ceftaroline fosamil-yielding new hope in the fight against a persistent infection. Expert Rev Anti Infect Ther 12:727-729. http://dx.doi.org/10.1586/14787210.2014.908118.
15. Casapao AM, Steed ME, Levine DP, Rybak MJ. 2012. Ceftaroline fosamil for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infection. Expert Opin Pharmacother 13:1177-1186. http://dx.doi.org/10.1517/14656566.2012.685718.
16. Goodman JJ, Martin SI. 2012. Critical appraisal of ceftaroline in the management of community-acquired bacterial pneumonia and skin infections. Ther Clin Risk Manag 8:149-156. http://dx.doi.org/10.2147/TCRM.S17413.
17. Shirley DT, Heil EL, Johnson JK. 2013. Ceftaroline fosamil: a brief clinical review. Infect Dis Ther 2:95-110. http://dx.doi.org/10.1007/s40121-013-0010-x.
18. Casapao AM, Davis SL, Barr VO, Klinker KP, Goff DA, Barber KE, Kaye KS, Mynatt RP, Molloy LM, Pogue JM, Rybak MJ. 2014. Large retrospective evaluation of the effectiveness and safety of ceftaroline fosamil therapy. Antimicrob Agents Chemother 58:2541-2546. http://dx.doi.org/10.1128/AAC.02371-13.
19. File TM, Jr, Wilcox MH, Stein GE. 2012. Summary of ceftaroline fosamil clinical trial studies and clinical safety. Clin Infect Dis 55(Suppl 3):S73-S80. http://dx.doi.org/10.1093/cid/cis559.
20. Actavis, Inc. 2012. Teflaro (ceftaroline fosamil) prescribing information. Actavis, Inc, Parsippany, NJ. http://www.frx.com/pi/teflaro-pi.pdf.
21. Astra Zeneca. 2012. Zinforo (ceftaroline fosamil). Summary of product characteristics. Astra Zeneca, Luton, United Kingdom. http://www.medicines.org.uk/emc/searchresults.aspx?term-Zinforo& searchtype-QuickSearch.
22. Bally M, Dendukuri N, Sinclair A, Ahern SP, Poisson M, Brophy J. 2012. A network meta-analysis of antibiotics for treatment of hospitalised patients with suspected or proven methicillin-resistant Staphylococcus aureus infection. Int J Antimicrob Agents 40:479-495. http://dx.doi.org/10.1016/j.ijantimicag.2012.08.004.
23. Critchley IA, Eckburg PB, Jandourek A, Biek D, Friedland HD, Thye DA. 2011. Review of ceftaroline fosamil microbiology: integrated FOCUS studies. J Antimicrob Chemother 66(Suppl 3):45-51. http://dx.doi.org/10.1093/jac/dkr098.
24. Frampton JE. 2013. Ceftaroline fosamil: a review of its use in the treatment of complicated skin and soft tissue infections and communityacquired pneumonia. Drugs 73:1067-1094. http://dx.doi.org/10.1007/s40265-013-0075-6.
25. Lodise TP, Low DE. 2012. Ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. Drugs 72:1473-1493. http://dx.doi.org/10.2165/11635660-000000000-00000.
26. Pasquale TR, Tan MJ, Trienski TL, File TM, Jr. 2015. Methicillinresistant Staphylococcus aureus nosocomial pneumonia patients treated with ceftaroline: retrospective case series of 10 patients. J Chemother 27: 29-34. http://dx.doi.org/10.1179/1973947813Y.0000000156.
27. Santos PD, Davis A, Jandourek A, Smith A, Friedland HD. 2013. Ceftaroline fosamil and treatment of acute bacterial skin and skin structure infections: CAPTURE study experience. J Chemother 25:341-346. http://dx.doi.org/10.1179/1973947813Y.0000000144.
28. Zhong NS, Sun T, Zhuo C, D'Souza G, Lee SH, Lan NH, Chiang CH, Wilson D, Sun F, Iaconis J, Melnick D. 2015. Ceftaroline fosamil versus ceftriaxone for the treatment of Asian patients with community-acquired pneumonia: a randomised, controlled, double-blind, phase 3, noninferiority with nested superiority trial. Lancet Infect Dis 15:161-171. http://dx.doi.org/10.1016/S1473-3099(14)71018-7.
29. Clinical and Laboratory Standards Institute. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standards, 9th ed. CLSI document M07-A9. Clinical and Laboratory Standards Institute, Wayne, PA.
30. Clinical and Laboratory Standards Institute. 2014. Performance standards for antimicrobial susceptibility testing; 24th informational supplement. CLSI document M100-S24. Clinical and Laboratory Standards Institute, Wayne, PA.
31. Alm RA, McLaughlin RE, Kos VN, Sader HS, Iaconis JP, Lahiri SD. 2014. Analysis of Staphylococcus aureus clinical isolates with reduced susceptibility to ceftaroline: an epidemiological and structural perspective. J Antimicrob Chemother 69:2065-2075. http://dx.doi.org/10.1093/jac/dku114.
32. Otero LH, Rojas-Altuve A, Llarrull LI, Carrasco-López C, Kumarasiri M, Lastochkin E, Fishovitz J, Dawley M, Hesek D, Lee M, Johnson JW, Fisher JF, Chang M, Mobashery S, Hermoso JA. 2013. How allosteric control of Staphylococcus aureus penicillin binding protein 2a enables methicillin resistance and physiological function. Proc Natl Acad Sci USA 110:16808-16813. http://dx.doi.org/10.1073/pnas.1300118110.
33. Long SW, Olsen RJ, Mehta SC, Palzkill T, Cernoch PL, Perez KK, Musick WL, Rosato AE, Musser JM. 2014. PBP2a mutations causing high-level ceftaroline resistance in clinical methicillin-resistant Staphylococcus aureus isolates. Antimicrob Agents Chemother 58:6668-6674. http://dx.doi.org/10.1128/AAC.03622-14.
34. Flamm RK, Sader HS, Jones RN. 2014. Ceftaroline activity tested against contemporary Latin American bacterial pathogens (2011). Braz J Infect Dis 18:187-195. http://dx.doi.org/10.1016/j.bjid.2013.11.005.
35. Fishovitz J, Rohas-Altuve A, Otero L, Dawley M, Carrasco-Lopez C, Chang M, Hermoso JA, Mobashery S. 2014. Disruption of allosteric response as an unprecedented mechanism of resistance to antibiotics. J Am Chem Soc 136:9814-9817. http://dx.doi.org/10.1021/ja5030657.
36. Dabul AN, Camargo IL. 2014. Molecular characterization of methicillinresistant Staphylococcus aureus resistant to tigecycline and daptomycin isolated in a hospital in Brazil. Epidemiol Infect 142:479-483. http://dx.doi.org/10.1017/S0950268813001325.
37. Sola C, Saka HA, Cordoba MRSA Collaborative Study Group, Vindel A, Bocco JL. 2008. Emergence and dissemination of a community-associated methicillin-resistant Panton-Valentine leucocidin-positive Staphylococcus aureus clone sharing the sequence type 5 lineage with the most prevalent nosocomial clone in the same region of Argentina. J Clin Microbiol 46:1826-1831. http://dx.doi.org/10.1128/JCM.01949-07.
38. Sola C, Paganini H, Egea AL, Moyano AJ, Garnero A, Kevric I, Culasso C, Vindel A, Study Group of CA-MRSA in Children, Argentina-2007, Lopardo H, Bocco JL. 2012. Spread of epidemic MRSA-ST5-IV clone encoding PVL as a major cause of community onset staphylococcal infections in Argentinean children. PLoS One 7:e30487. http://dx.doi.org/10.1371/journal.pone.0030487.